AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
ACADIA Pharmaceuticals Inc.
Video analysis: ACAD
All videosNo video analysis for this stock yet. Request one from our team.
News: ACAD
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Alyeska Investment Group L.P. Purchases Shares of 310,287 ACADIA Pharmaceuticals Inc. $ACAD
Alyeska Investment Group L.P. purchased a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 310,287 shares of the biopharmaceutical company's stock, valued at approximately $7,850,000. Alyeska Investment Group L.P. owned about 0.18% of ACADIA
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
ACAD secures EC approval for Daybu, the first and only treatment approved in the EU for Rett syndrome, expanding its geographical reach.
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the
BlackRock Inc. Purchases Shares of 22,515,173 ACADIA Pharmaceuticals Inc. $ACAD
BlackRock Inc. acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 22,515,173 shares of the biopharmaceutical company's stock, valued at approximately $569,634,000. BlackRock Inc. owned 13.15% of ACADIA Pharmaceuticals
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and ad.
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer's Data
ACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer's disease psychosis during a discussion hosted by Canaccord Genuity.
Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?
Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
